Edgewise Therapeutics (EWTX) Change in Account Payables (2020 - 2026)

Edgewise Therapeutics has reported Change in Account Payables over the past 7 years, most recently at $1.4 million for Q1 2026.

  • Quarterly results put Change in Account Payables at $1.4 million for Q1 2026, down 49.41% from a year ago — trailing twelve months through Mar 2026 was -$1.1 million (down 129.88% YoY), and the annual figure for FY2025 was $272000.0, down 84.34%.
  • Change in Account Payables reached $1.4 million in Q1 2026 per EWTX's latest filing, up from -$303000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.9 million in Q1 2025 and bottomed at -$2.7 million in Q2 2022.
  • Median Change in Account Payables over the past 5 years was $92000.0 (2024), compared with a mean of $200588.2.
  • The largest annual shift saw Change in Account Payables surged 1985.71% in 2022 before it crashed 429.35% in 2025.
  • Over 5 years, Change in Account Payables stood at $576000.0 in 2022, then tumbled by 339.93% to -$1.4 million in 2023, then soared by 106.66% to $92000.0 in 2024, then plummeted by 429.35% to -$303000.0 in 2025, then soared by 577.23% to $1.4 million in 2026.
  • Business Quant data shows Change in Account Payables for EWTX at $1.4 million in Q1 2026, -$303000.0 in Q4 2025, and -$2.1 million in Q3 2025.